Clovis Oncology, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|---|---|
| Revenue | $38.1M | $42.6M | $143.0M | $95.4M | $55.5M | $78,000 |
| Operating income | −$58.0M | −$82.0M | −$376.7M | −$333.8M | −$237.6M | −$372.7M |
| Net income | −$66.3M | −$99.3M | −$400.4M | −$368.0M | −$346.4M | −$349.1M |
| Total assets | $472.8M | $605.6M | $669.6M | $863.6M | $735.2M | $364.6M |
| Total liabilities | $751.7M | $764.3M | $843.9M | $717.1M | $367.6M | $368.2M |
| Equity | −$278.8M | −$158.7M | −$174.3M | $146.5M | $367.6M | −$3.6M |
| EPS (diluted) | $-0.64 | $-1.39 | $-7.43 | — | — | — |
| Shares out. | 104.5M | 73.4M | 52.9M | 50.6M | 44.6M | 38.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- −152.4%
- Net margin
- −174.2%
- Return on equity
- 23.8%
- Return on assets
- −14.0%
- Return on capital (ROCE)
- −16.7%
- Liabilities / assets
- 159.0%
- Debt / equity
- —
- Book value / share
- $-2.67
- Revenue growth (YoY)
- −10.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- -20.04distress
- Accruals / assets
- 27.4%high accruals
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 6 warning● 1 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
- Strong return on equity (>15%)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Bankruptcy or receivership · Modified shareholder rights · Change in control · Director / officer change · Other material eventJul 11, 2023
- Modified shareholder rights · Regulation FD disclosureJun 30, 2023
- Regulation FD disclosure · Other material eventJun 2, 2023
- Regulation FD disclosureMay 3, 2023
- Completed an acquisition or dispositionMay 1, 2023
- Completed an acquisition or dispositionApr 14, 2023
- Entered a material agreementApr 6, 2023
- Regulation FD disclosureMar 31, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.